About: Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 24 April 2012

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2012 (ast) наукова стаття, опублікована у квітні 2012 (uk) scientific article published on 24 April 2012 (en) مقالة علمية نشرت في 24 أبريل 2012 (ar)
publication date	wds:Q37383528-4B194EC0-5F28-4D57-BE0E-5ECF9E1555DD
publication date	2012-04-24 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37383528-95827C6B-7C2A-4DE8-BA6F-3D5D7E941F7D
language of work or name	English
cites work	wds:Q37383528-00F8642E-9F76-409D-A7F1-D5F61C59B1C9 wds:Q37383528-029BE698-6055-4155-B163-C751844F1D19 wds:Q37383528-0A4F32B3-9648-40EE-A897-882A469B7934 wds:Q37383528-0A7D005F-80EC-45FB-A110-4A140E2C892A wds:Q37383528-1904BF45-3CD6-4523-8765-918B6FB20E9E wds:Q37383528-197FEBD2-8E1D-4554-A8FC-1175C76FE47D wds:Q37383528-22CC3E5A-F9D7-4B97-9028-4D4E41C5CEC1 wds:Q37383528-43F13696-7081-43B8-BA51-513A10766C88 wds:Q37383528-504449F2-4852-4FC7-AE0A-4F8E4FE644D4 wds:Q37383528-602BB25D-060A-4668-97E7-9802B19D39B0 wds:Q37383528-64664D17-3B3F-4087-B6CF-2B10AB42421C wds:Q37383528-8817E3D1-81A8-415B-9E05-E2CD52728EAC wds:Q37383528-8972AC24-363D-45A7-A78D-BB6F78B30E1F wds:Q37383528-8E04F3E2-D18A-4A8E-944B-E81ACE70FDDA wds:Q37383528-AF147750-7C9E-411C-B548-BA7BEB25FC24 wds:Q37383528-B973616B-D9B6-41F2-A4B5-1DF44CD99627 wds:Q37383528-E0D36738-4DD1-4016-8395-6620501EEF66 wds:Q37383528-F18FB36B-1604-45C7-B7A8-F28B08047804 wds:Q37383528-F5862DC3-3676-4AAB-B19D-B82BB5977420
cites work	Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence Outcome of patients with acute myelogenous leukemia after second salvage therapy Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy Treatment of relapsed and refractory acute myelogenous leukemia Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types How I treat older patients with AML Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy
author name string	wds:Q37383528-1E141D19-11DA-4C38-A67D-B5B93B5DD2BC
author name string	Varsha Gandhi
rdfs:label	Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia (en) Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia (nl) Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia (ast)
skos:prefLabel	Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia (en) Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia (nl) Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia (ast)
name	Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia (en) Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia (nl) Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia (ast)
author	wds:Q37383528-03CADE61-F412-4418-9F3D-002104AFCF92 wds:Q37383528-17F45722-58AF-4EC2-8A4C-F1EAF94DEFCA wds:Q37383528-361B007F-6D64-4A16-98E7-7D488073921F wds:Q37383528-46DC58FD-A3F5-43CD-85C3-71708D18209A wds:Q37383528-4BE04195-B55E-4AF9-8435-DC7068DE7517 wds:Q37383528-4DC595E7-1ABF-4132-A211-9B0FA3D00905 wds:Q37383528-5D019E54-9E7C-4F00-B7FD-7DA4BF7484C4 wds:Q37383528-72387085-C9DE-409B-9DC0-5358EFC3EA41 wds:Q37383528-80448782-ED6C-4D6A-8445-5E8063B5EEBD wds:Q37383528-9CA979A4-5F73-45F4-A02D-E031E40C12B0 wds:Q37383528-AFD485B6-AB0A-4BF0-95B9-0E04B48714E2 wds:Q37383528-B90E9347-A1C7-4996-9295-B7A59CC6DDD0 wds:Q37383528-BD39A9F5-4897-4F96-BD47-E7334F4217DF wds:Q37383528-E64DDB20-1AF2-4635-AA96-4F824B9130B3
author	Marina Konopleva Farhad Ravandi Susan O'Brien Elias Jabbour Stefan Faderl Xuelin Huang Gautam Borthakur William Plunkett Jorge Eduardo Cortes Hagop Kantarjian Guillermo Garcia-Manero Mark J Brandt Jan A Burger Tapan Kadia
title	wds:Q37383528-1AE16FB8-B2D5-4358-81F5-DB34EB1E516E
title	Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia (en)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software